Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 145.99 $ 0.41 (0.28 %)    

Monday, 17-Jun-2024 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 484.61 $ 5.87 (1.22 %)
DIA $ 388.55 $ 2.12 (0.55 %)
SPY $ 547.02 $ 4.32 (0.8 %)
TLT $ 93.72 $ -0.94 (-0.99 %)
GLD $ 214.57 $ -1.12 (-0.52 %)
$ 145.95
$ 145.10
$ 0.00 x 0
$ 0.00 x 0
$ 144.78 - $ 146.36
$ 141.57 - $ 170.63
6,666,583
na
354.67B
$ 0.48
$ 9.22
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-16-2024 12-31-2023 10-K
3 10-27-2023 10-01-2023 10-Q
4 10-27-2023 10-01-2023 10-Q
5 07-31-2023 07-02-2023 10-Q
6 04-28-2023 04-02-2023 10-Q
7 02-16-2023 01-01-2023 10-K
8 10-27-2022 10-02-2022 10-Q
9 07-29-2022 07-03-2022 10-Q
10 04-29-2022 04-03-2022 10-Q
11 02-17-2022 01-02-2022 10-K
12 10-29-2021 10-03-2021 10-Q
13 07-29-2021 07-04-2021 10-Q
14 04-30-2021 04-04-2021 10-Q
15 02-22-2021 01-03-2021 10-K
16 10-23-2020 09-27-2020 10-Q
17 07-24-2020 06-28-2020 10-Q
18 04-29-2020 03-29-2020 10-Q
19 02-18-2020 12-29-2019 10-K
20 10-28-2019 09-29-2019 10-Q
21 07-29-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-20-2019 12-30-2018 10-K
24 10-31-2018 09-30-2018 10-Q
25 08-02-2018 07-01-2018 10-Q
26 05-01-2018 04-01-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-02-2017 10-01-2017 10-Q
29 08-03-2017 07-02-2017 10-Q
30 05-08-2017 04-02-2017 10-Q
31 02-27-2017 01-01-2017 10-K
32 11-04-2016 10-02-2016 10-Q
33 08-04-2016 07-03-2016 10-Q
34 05-10-2016 04-03-2016 10-Q
35 02-24-2016 01-03-2016 10-K
36 10-30-2015 09-27-2015 10-Q
37 07-31-2015 06-28-2015 10-Q
38 05-01-2015 03-29-2015 10-Q
39 02-24-2015 12-28-2014 10-K
40 10-30-2014 09-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

legend-biotechs-cancer-drug-the-most-attractive-product-set-for-growth-analyst
Legend Biotech's Cancer Drug, 'The Most At...
06/17/2024 16:15:05

Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product.

whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday
What's Going On With Small-Cap Cancer Focu...
06/17/2024 15:47:08

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

market-analysis-johnson-amp-johnson-and-competitors-in-pharmaceuticals-industry
Market Analysis: Johnson & Johnson And...
06/17/2024 15:00:48

in-depth-examination-of-11-analyst-recommendations-for-johnson--johnson
In-Depth Examination Of 11 Analyst Recomme...
06/17/2024 14:01:28

rbc-capital-reiterates-outperform-on-johnson--johnson-maintains-175-price-target
RBC Capital Reiterates Outperform on Johns...
06/17/2024 13:04:23

RBC Capital analyst Shagun Singh reiterates Johnson & Johnson (NYSE:JNJ) with a Outperform and maintains $175 price target.

johnson--johnson-submits-an-fda-application-for-fixed-combination-of-amivantamab-and-recombinant-human-hyaluronidase-for-subcutaneous-administration-for-all-currently-approved-or-submitted-indications-of-iv-rybrevant-in-certain-type-of-nsclc
Johnson & Johnson Submits An FDA Applicati...
06/17/2024 12:04:20

reported-saturday-johnson--johnsons-phase-2-dahlias-study-reveals-nipocalimab-yields-over-70-improvement-in-sjgrens-disease-activity-compared-to-placebo
Reported Saturday, Johnson & Johnson's Pha...
06/17/2024 07:55:09

Patients who received nipocalimab 15 mg/kg demonstrated a greater than 70 percent relative average improvement on the primary...

jj-reports-updated-phase-2-captivate-study-results-show-sustained-clinical-benefit-of-fixed-duration-imbruvica-plus-venetoclax
J&J Reports Updated Phase 2 CAPTIVATE Stud...
06/14/2024 20:22:21

- Reuters

Core News & Articles
FDA On June 13 Updates Advice To Manufactu...
06/14/2024 18:13:02

- Reuters

johnson--jonson-reports-long-term-data-from-phase-12-monumental-1-study
Johnson & Jonson Reports Long-term Data Fr...
06/14/2024 12:04:01

how-is-the-market-feeling-about-johnson--johnson
How Is The Market Feeling About Johnson & ...
06/13/2024 16:15:24

Core News & Articles
Xencor Has Been Notified Janssen Will Term...
06/13/2024 12:09:35

ovarian-cancer-victims-file-motion-to-halt-johnson--johnsons-new-bankruptcy-filing-outside-new-jersey-citing-further-compensation-delays
Ovarian Cancer Victims File Motion To Halt...
06/12/2024 18:27:47

wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-delivering-high-dividend-yields
Wall Street's Most Accurate Analysts Spotl...
06/12/2024 13:15:52

johnson--johnson-to-pay-700m-to-settle-multi-state-talc-investigation
Johnson & Johnson To Pay $700M To Settle M...
06/12/2024 11:53:23

Although the settlement has been reached, Johnson & Johnson still faces a substantial number of talc-related lawsuits.

johnson--johnson-reaches-700m-settlement-with-most-us-states-for-alleged-deceptive-marketing-of-talc-containing-products-massachusetts-attorney-general-says
Johnson & Johnson Reaches $700M Settlement...
06/11/2024 17:11:05

- Reuters Citing Court Documents 

new-york-attorney-general-files-lawsuit-against-johnson--johnson
New York Attorney General Files Lawsuit Ag...
06/11/2024 17:07:36

- Reuters Citing Court Documents 

Core News & Articles
FDA Advised Manufacturers Of Authorized Co...
06/07/2024 14:47:41

- Reuters

abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-biosimilar-industry-viability
AbbVie's Arthritis Drug Humira Retains Mar...
06/07/2024 14:39:05

Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...

johnson--johnson-medtechs-depuy-synthes-receives-fda-clearance-for-velys-robotic-assisted-solution-in-unicompartmental-knee-arthroplasty-uka
Johnson & Johnson MedTech's DePuy Synthes ...
06/07/2024 12:05:17

https://www.jnj.com/media-center/press-releases/depuy-synthes-receives-510k-fda-clearance-of-the-velys-robotic-assisted-solutio...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)